Skip to main content

Deep and ultra-deep PSA responses as prognostic biomarkers in metastatic hormone-sensitive prostate cancer. A systematic review and implications for treatment personalization

In brief

Very low PSA after treatment marks longer survival in metastatic prostate cancer

Across 65 studies, reaching a PSA of 0.2 ng/mL or lower, including ultra-low levels of 0.02 ng/mL or lower, was consistently linked to longer survival and slower cancer progression. The findings support PSA response as an accessible prognostic marker, but differing assessment schedules and thresholds limit comparisons; ongoing trials will test whether changing treatment based on PSA improves outcomes.

Journal
Cancer treatment reviews (Q1)
Published
21 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Jorge Esteban-Villarrubia, Fanghui Wu Jin, David Lorente, David Olmos, Daniel Castellano, Alfredo Rodriguez-Antolin, et al.
PMID
43002974
DOI
10.1016/j.ctrv.2026.103236

Why clinicians should know about it

  • Picked for Urology (top studies of the week, 15 November 2026): Systematic review of PSA response prognostic value in metastatic prostate
  • Picked for Biochemistry (medical) (paper of the day, 10 November 2026): PSA response thresholds and dynamics as clinical biomarkers

Abstract

BACKGROUND: Metastatic hormone-sensitive prostate cancer (mHSPC) exhibits heterogeneous outcomes despite standard androgen deprivation therapy (ADT) and widespread first-line intensification with androgen-receptor pathway inhibitors (ARPIs) and/or docetaxel. Simple, widely accessible biomarkers are needed to individualize care (intensification vs de-intensification). We systematically reviewed the prognostic value of post-therapy PSA dynamics-particularly deep (≤ 0.2 ng/mL) and ultra-deep (≤ 0.02 ng/mL) PSA responses-and their potential role to inform future predictive strategies. METHODS: We searched MEDLINE and EMBASE for randomized trials and observational studies in mHSPC treated with ADT alone or combined with chemotherapy, ARPIs and/or radiotherapy to the primary tumor. Primary outcomes were overall survival (OS), radiographic progression-free survival (rPFS)/PFS, and time to castration resistance (TTCR). Post-therapy PSA assessment windows varied across studies (typically 3-7 months), and the anchoring time point was either ADT initiation or randomization (with variable prior ADT exposure). In addition, we reviewed clinicaltrials.gov for PSA-guided treatment adaptative ongoing clinical trials. RESULTS: Of 785 records identified, 65 references met the eligibility criteria, corresponding to 16 phase III randomized trials, 1 meta-analysis and 42 retrospective studies. The phase III trials evaluated different treatment strategies, including ADT alone, ADT plus docetaxel, ADT plus androgen receptor pathway inhibitors (ARPIs; apalutamide, abiraterone, darolutamide, enzalutamide, or rezvilutamide), and triplet therapy. Across trials, deep and ultradeep early PSA responses were consistently associated with longer rPFS and OS. Conversely, higher PSA nadirs or incomplete early PSA responses predicted earlier progression and shorter survival. Observational cohorts showed concordant findings. In addition, eight landmark PSA-guided adaptive randomized clinical trials (seven ongoing or planned and one recently reported) were summarized, including treatment de-escalation strategies for patients with optimal PSA responses and treatment intensification strategies for those with suboptimal PSA responses. CONCLUSIONS: Achieving a deep or ultra-deep PSA response after starting systemic therapy is a robust and affordable prognostic indicator in mHSPC. Harmonization of PSA assessment windows and thresholds is crucial. Ongoing randomized trials will help to understand its utility for treatment personalization.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.